Source: Eur Respir J, 53 (6) 1800965; 10.1183/13993003.00965-2018
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Rita Papp, Chandran Nagaraj, Diana Zabini, Bence M. Nagy, Miklós Lengyel, Davor Skofic Maurer, Neha Sharma, Bakytbek Egemnazarov, Gabor Kovacs, Grazyna Kwapiszewska, Leigh M. Marsh, Andelko Hrzenjak, Gerald Höfler, Miroslava Didiasova, Malgorzata Wygrecka, Laura K. Sievers, Peter Szucs, Péter Enyedi, Bahil Ghanim, Walter Klepetko, Horst Olschewski, Andrea Olschewski. Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension. Eur Respir J, 53 (6) 1800965; 10.1183/13993003.00965-2018

Member's Comments

No comment yet.

Related content which might interest you: Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020 Year: 2021 CFTR involvement in the pathogenesis of pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Vascular reverse remodeling in the mouse model of hypoxia-induced pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (2) 2101645; 10.1183/13993003.01645-2021 Year: 2021 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 Endothelial NO and its pathophysiologic regulation Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Exercise limitation in idiopathic pulmonary arterial hypertension (IPAH): there‘s more to it than just the pulmonary circulation Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 6-8 Year: 2010 Contribution of angiopoietin/Tie2 pathway to pulmonary artery smooth muscle hyperplasia in idiopathic pulmonary hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Molecular determinants of cardiac and pulmonary vascular remodeling in scleroderma-related pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension in connective tissue diseases Year: 2008 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014